NEW YORK (GenomeWeb) – VolitionRx today announced a collaboration with the University of Texas MD Anderson Cancer Center's Department of Genitourinary Medical Oncology to evaluate the use of the firm's NuQ assay to distinguish anaplastic prostate cancer from typical castration-resistance prostate cancer (CRPC).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.